2007 Stock Overview
Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People’s Republic of China.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 3/6 |
Past Performance | 5/6 |
Financial Health | 5/6 |
Dividends | 4/6 |
Hualan Biological Engineering Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥19.81 |
52 Week High | CN¥25.09 |
52 Week Low | CN¥16.51 |
Beta | 0.30 |
1 Month Change | 0.61% |
3 Month Change | -10.48% |
1 Year Change | -6.20% |
3 Year Change | -50.62% |
5 Year Change | -13.66% |
Change since IPO | 1,820.05% |
Recent News & Updates
Shareholder Returns
2007 | CN Biotechs | CN Market | |
---|---|---|---|
7D | -0.6% | -6.3% | -4.9% |
1Y | -6.2% | -21.2% | -16.6% |
Return vs Industry: 002007 exceeded the CN Biotechs industry which returned -21.2% over the past year.
Return vs Market: 002007 exceeded the CN Market which returned -16.6% over the past year.
Price Volatility
2007 volatility | |
---|---|
2007 Average Weekly Movement | 3.9% |
Biotechs Industry Average Movement | 8.1% |
Market Average Movement | 8.2% |
10% most volatile stocks in CN Market | 11.5% |
10% least volatile stocks in CN Market | 5.1% |
Stable Share Price: 002007 has not had significant price volatility in the past 3 months.
Volatility Over Time: 002007's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1992 | 3,243 | Bei Fan | https://www.hualanbio.com |
Hualan Biological Engineering Inc., a biopharmaceutical company, researches, develops, produces, and commercializes plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics in the People’s Republic of China. Its blood products comprise human albumin, human immunoglobulin, intravenous human immunoglobulin, rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, human prothrombin complex, human coagulation factor VIII, lyophilized human thrombin for external use, freeze-dried human fibrin glue for surgery, and human fibrinogen. The company’s vaccines consist of influenza virus split vaccine, recombinant hepatitis B vaccine, ACYW135 meningococcal polysaccharide vaccine, A H1N1 influenza virus split vaccine, and quadrivalent influenza virus split vaccine.
Hualan Biological Engineering Inc. Fundamentals Summary
2007 fundamental statistics | |
---|---|
Market cap | CN¥35.42b |
Earnings (TTM) | CN¥1.24b |
Revenue (TTM) | CN¥4.83b |
29.1x
P/E Ratio7.5x
P/S RatioIs 2007 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2007 income statement (TTM) | |
---|---|
Revenue | CN¥4.83b |
Cost of Revenue | CN¥1.70b |
Gross Profit | CN¥3.13b |
Other Expenses | CN¥1.88b |
Earnings | CN¥1.24b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 30, 2024
Earnings per share (EPS) | 0.68 |
Gross Margin | 64.78% |
Net Profit Margin | 25.75% |
Debt/Equity Ratio | 7.0% |
How did 2007 perform over the long term?
See historical performance and comparison